...
首页> 外文期刊>Seminars in Respiratory and Critical Care Medicine >Fungi in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
【24h】

Fungi in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis

机译:囊性纤维化和非囊性纤维化支气管扩张的真菌

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Bronchiectasis is a pathologic bronchial dilatation with loss of function that can result from multiple inflammatory and infectious injuries to the conducting airways of the lung. Molds, particularly the filamentous fungus Aspergillus fumigatus, have been implicated as a common cause of both cystic fibrosis (CF) and non-CF bronchiectasis, the latter primarily in patients with severe asthma. The pathogenesis of mold-associated bronchiectasis is usually due to atopic sensitization to mold allergens in the presence of active chronic endobronchial fungal infection with host innate and adaptive immune deviation to a Th2-dominated inflammation, a condition known as allergic bronchopulmonary aspergillosis (ABPA) (or allergic bronchopulmonary mycosis if a non-Aspergillus mold is implicated). Diagnostic criteria of ABPA continue to evolve, while treatment relies upon downregulation of the allergic inflammatory response with immunomodulatory agents and antifungal pharmacotherapy.
机译:支气管扩张是一种病理性支气管扩张,其功能丧失可能是由于对肺部导气管的多种炎症和感染性损伤所致。霉菌,特别是丝状真菌烟曲霉,被认为是囊性纤维化(CF)和非CF支气管扩张的常见原因,后者主要发生在严重哮喘患者中。霉菌相关性支气管扩张的发病机制通常是由于在存在慢性慢性支气管内真菌感染,宿主先天性和针对Th2为主的炎症的适应性免疫偏离的情况下对霉菌过敏原的过敏性致敏,这种疾病称为过敏性支气管肺曲霉菌病(ABPA)(或与非曲霉霉菌有关的过敏性支气管肺真菌病)。 ABPA的诊断标准继续发展,而治疗依赖于免疫调节剂和抗真菌药物疗法对过敏性炎症反应的下调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号